M. tuberculosis Immunodominant Antigen Panels for Diagnostic Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing tuberculosis (TB) are inadequate due to variability in immune responses, lack of specificity and sensitivity, and inability to differentiate between active and latent infections, and existing vaccines face challenges with individual immune response variability and coverage issues.
Innovation Solution
Development of immunodominant antigens from Mycobacterium tuberculosis, specifically encoded by nucleic acids with known reactivities, which are used in diagnostic assays and vaccine compositions to elicit a strong immune response and provide clear disease parameter associations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If single antigens are used for TB diagnosis, then the test is simple to perform, but the diagnostic accuracy and specificity are insufficient due to individual immune response variability
Solution Approach 1:
The patent combines multiple TB antigens (including ESAT-6, CFP-10, and other immunodominant antigens) into a single diagnostic test panel. This merging approach allows the test to detect diverse immune responses across different individuals, overcoming the limitation of single-antigen tests while maintaining operational simplicity through a unified assay format.
Solution Approach 2:
The multi-antigen diagnostic composition serves multiple functions: it can detect both latent and active TB infections, differentiate between BCG-vaccinated and naturally infected individuals, and provide results applicable across diverse populations with varying immune responses. This universal applicability resolves the contradiction between test simplicity and diagnostic accuracy.
2Measurement precision
If multiple tests are used for accurate TB diagnosis, then diagnostic accuracy improves, but the complexity of the diagnostic process increases
Solution Approach 1:
The patent merges multiple diagnostic capabilities into a single integrated assay. By incorporating multiple antigens that target different aspects of TB immunity (cell-mediated, humoral, early vs. late stage responses), the test achieves the diagnostic accuracy of multiple separate tests while simplifying the overall diagnostic workflow into one procedure.
Solution Approach 2:
The diagnostic composition performs multiple diagnostic functions simultaneously: it can distinguish between latent and active infection, differentiate BCG vaccination from natural infection, and provide results for various patient populations. This multi-functionality eliminates the need for sequential testing while maintaining high diagnostic accuracy.
3Ease of manufacture
If conventional antigens are used, then the test can be performed with standard equipment, but the ability to differentiate between active and latent infection is insufficient
Solution Approach 1:
The patent employs antigens with distinct immunological profiles that are locally optimized for detecting specific infection stages. Certain antigens (e.g., ESAT-6, CFP-10) are particularly responsive to active infection, while others provide signals characteristic of latent infection or BCG vaccination. This local specialization within the antigen panel enables differentiation of infection stages while maintaining test accessibility.
Solution Approach 2:
The diagnostic test detects changes in antibody responses to different antigens over time and across infection stages. By measuring the pattern and magnitude of responses to multiple antigens, the test can distinguish between active and latent infection based on the immunological parameter profiles, even using standard laboratory equipment.
4Ease of manufacture
If single antigen vaccines are used, then the vaccine is simple to produce, but coverage is limited due to individual immune response variability
Solution Approach 1:
The vaccine composition merges multiple immunodominant antigens (including ESAT-6, CFP-10, and other M. tuberculosis-specific proteins) into a single vaccine formulation. This combination approach ensures that individuals with different immune response profiles will recognize at least some of the antigens, thereby expanding protective coverage while maintaining relatively simple production processes.
Solution Approach 2:
The multi-antigen vaccine provides universal protection across diverse populations by targeting multiple conserved antigens that are recognized by different immune mechanisms. This approach ensures broad adaptability to various host immune responses while keeping the vaccine formulation and production process manageable.
Data Source
AI summary
Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.